Head-to-head evidence
Ralinepag vs Treprostinil (Yutrepia, Liquidia)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Hypertension pipeline
Ralinepag
Developed by United Therapeutics
NCT03626688 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 687 participants, measuring time to a clinical worsening event as the primary endpoint. The sponsor reports a 55% reduction in the risk of clinical worsening for ralinepag versus placebo, a statistically significant result.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT03683186 (registry estimate)
Treprostinil (Yutrepia, Liquidia)
Marketed by Liquidia Corporation
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2027 · NCT07759804 (registry estimate)
Pulmonary Arterial Hypertension
Shared mechanism: IP receptor (prostacyclin pathway) · full Pulmonary Arterial Hypertension pipeline
Ralinepag
Developed by United Therapeutics
NCT03626688 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 687 participants, measuring time to a clinical worsening event as the primary endpoint. The sponsor reports a 55% reduction in the risk of clinical worsening for ralinepag versus placebo, a statistically significant result.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT03683186 (registry estimate)
Treprostinil (Yutrepia, Liquidia)
Marketed by Liquidia Corporation
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05649748 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ralinepag's landscape · Treprostinil (Yutrepia, Liquidia)'s landscape